
Catalyst Pharmaceuticals (CPRX) Stock Forecast & Price Target
Catalyst Pharmaceuticals (CPRX) Analyst Ratings
Bulls say
Catalyst Pharmaceuticals Inc demonstrated a strong financial performance with total revenue of $141.8 million for the fourth quarter of 2024, reflecting a year-over-year increase of approximately 28.3%. The company is poised for continued growth, particularly through the expansion of FIRDAPSE into the cancer-associated LEMS market and the promising early momentum of AGAMREE's launch, which has shown significant penetration in the Duchenne Muscular Dystrophy (DMD) market. The ongoing demand for both FYCOMPA and new strategic opportunities in the orphan disease sector position Catalyst for sustained value creation and robust financial performance moving forward.
Bears say
The analysis indicates a negative outlook for Catalyst Pharmaceuticals Inc., primarily due to the potential inability to defend its drug portfolio, which poses a risk of losing market potential for its products. Additionally, concerns regarding access to capital and funding could hinder essential business functions, delaying the company’s path to profitability and cash flow generation. Furthermore, the risks associated with clinical efficacy, competition, and reliance on third-party manufacturing could impede the achievement of expected commercial revenue from its key products, FIRDAPSE, FYCOMPA, and AGAMREE.
This aggregate rating is based on analysts' research of Catalyst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Catalyst Pharmaceuticals (CPRX) Analyst Forecast & Price Prediction
Start investing in Catalyst Pharmaceuticals (CPRX)
Order type
Buy in
Order amount
Est. shares
0 shares